RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients Prostate Cancer and Prostatic Diseases advance online publication, October 1 2013. doi:10.1038/pcan.2013.35 Authors: L A Kachnic, S L Pugh, P Tai, M Smith, E Gore, A B Shah, A-G Martin, H E Kim, A Nabid &C A F Lawton
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Tags: radiation therapy androgen deprivation therapy osteoporosis bone fractures Source Type: research

Related Links:

In conclusion, denosumab may reduce the risk of falls in addition to its established fracture risk reduction by reducing bone resorption and increasing bone mass. These observations require further exploration and confirmation in studies with muscle function or falls as the primary outcome.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
This study showed that both drugs significantly improved lumbar spine and total hip bone mineral density in Asian men with prostate cancer who received ADT.IntroductionTo evaluate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT.MethodsA multicenter, open-label, randomized, controlled study including patients with hormone-sensitive PCa without bone metastasis receiving ADT was performed. Patients were randomized (1:1:1) to minodronate, denosumab, or no agent control groups. The primary end point was t...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
AbstractPurpose of ReviewThe improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment –induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required.Recent FindingsThe principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. T...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to explore the role of monocyte chemoattractant protein-1 (MCP-1 or CCL2) in the processes that underpin bone remodelling, particularly the action of osteoblasts and osteoclasts, and its role in the development and metastasis of cancers that target the bone.Recent FindingsMCP-1 is a key mediator of osteoclastogenesis, being the highest induced gene during intermittent treatment with parathyroid hormone (iPTH), but also regulates catabolic effects of continuous PTH on bone including monocyte and macrophage recruitment, osteoclast formation and bone resorption. In concer...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Abstract Starting from their role exerted on osteoblast and osteoclast differentiation and activity pathways, microRNAs (miRNAs) have been recently identified as regulators of different processes in bone homeostasis. For this purpose, in a recent review, we highlighted, as deregulated miRNAs could be involved in different bone diseases such as osteoporosis. In addition, recent studies supported the concept that osteoporosis-induced bone alterations might offer a receptive site for cancer cells to form bone metastases, However, to date, no data on specific-shared miRNAs between osteoporosis and bone metastases have...
Source: Cellular and Molecular Life Sciences : CMLS - Category: Cytology Authors: Tags: Cell Mol Life Sci Source Type: research
Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients ’ quality of life, like sexual dysfunction, osteoporosis, weight gain...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
Osteoporosis is one of the most frequent diseases in postmenopausal women leading to an increased fracture risk due to the physiologic loss of the bone protective effects of estrogen. Hereby, several risk factors for fracture such as prevalent fracture, low BMD, age, low BMI, family history, tendency to falls, smoking, use of SSRIs, glucocorticoid use etc. have been identified. Additionally, the further reduction of endogenous hormones with chemotherapy (CHT) or GnRH-analoga continuously increases fracture risk.
Source: Maturitas - Category: Primary Care Authors: Tags: INV14 Source Type: research
AbstractEquol is a product formed during the biotransformation of the naturally occurring isoflavone daidzein by intestinal bacteria. The role of equol in the prevention of several hormone ‐dependent diseases such as prostate cancer and osteoporosis as well as vasomotor symptoms has been extensively investigated. Equol primarily occurs in the form of major metabolites such as glucuronides and sulfates, while intact equol has been detected at only ca. 1% in human plasma. However, to date, conjugated metabolites have been evaluated by measuring the free equol obtained after selective enzymatic hydrolysis. Thus, the precise...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Legislation | Orthopaedics | Osteoporosis | Prostate Cancer | Radiation Therapy | Reclast | Urology & Nephrology | Zometa